Polifarma S.p.A. has acquired 100% of the shares of Hennig Arzneimittel GmbH & Co. KG, a historic company based in Frankfurt specializing primarily in neurological and psychiatric drugs, operating also as a CDMO (Contract Development and Manufacturing Organization), with an excellent international presence.
The Italian company has taken control of the German enterprise located in the Rhine-Main area, ensuring operational continuity and industrial synergies.
Polifarma, with a familial and entrepreneurial history closely aligned with that of Hennig Arzneimittel, has built a strong and enduring relationship of mutual respect and collaboration with the German company. The sale was facilitated by the profound harmony between the two families, ensuring close cooperation throughout the transition process. This agreement represents the natural evolution of a nearly two-decade-long partnership, initiated in 2008 with the launch of two drugs for the treatment of vertigo.
“This investment confirms our commitment to building a future for the next generations – says Luisa Angelini, President of the Final Group. “This is a historic moment for Polifarma, now positioned within a new international dimension, anticipating a profound transformation that will reshape the company’s entire structure. Hennig’s entrepreneurial journey is a remarkable story of adaptability and international expansion, one that allows us to strengthen our global positioning and pave the way for growth and innovation by enhancing specific competencies. Furthermore, this investment will enable us to progressively establish our own production capacity, a strategic asset for greater control of the value chain.”
With a solid experience in pharmaceutical manufacturing and marketing, Hennig Arzneimittel is a recognized leader in the treatment of vertigo in Germany. Its strong market position is reflected in a gross revenue of approximately €60 million in 2024, with a constant increase in international sales. The company produces 5 billion tablets and 1 billion capsules annually, supported by a state-of-the-art production facility strategically located in Germany. With a team of approximately 300 employees, including 66 medical representatives, Hennig Arzneimittel has established a global presence in over 27 countries, generating a level of overall profitability in line with industry standards.
With the acquisition of Hennig Arzneimittel, Polifarma now unlocks significant growth opportunities. These include expanding its portfolio for the Italian market, developing commercial synergies in the German market and introducing new products while optimizing existing formulations. Additionally, the agreement offers the potential to activate production synergies, which could serve as a critical competitive advantage for the company’s future in terms of efficiency and supply chain control.
The entire operation was supported by Banca Patrimoni Sella & C., the Sella Group’s bank specializing in the management and administration of private and institutional client assets. Thanks to its experience and personalized consultancy, it played a key role in the financial coordination of the acquisition, providing strategic support for structuring the transaction.
For Polifarma, the transaction was completed with the assistance of Deloitte Financial Advisory, which acted as the exclusive financial advisor in M&A and Debt Advisory, and EY Law, which handled the legal aspects.
Hennig was assisted by RSM Ebner Stolz, acting as financial and legal advisor.
Loan Agency Services S.r.l. took on the role of agent bank in managing and monitoring the financial transaction.